Skip to content
AnalystLens

Rivian Automotive 8-K Report, Executive Changes (Nov 7, 2025)

Reports
Leadership Changes
Filing Date
Filed November 7, 2025
Period End
November 6, 2025
Security
RIVN
In the record · 2021–202610-K510-Q168-K86

RIVN filed 5 annual reports (10-K), 16 quarterly reports (10-Q) and 86 current reports (8-K) between 2021 and 2026.

  1. Material agreement8-K · Apr ’23Apr ’23
  2. Leadership change8-K · Jul ’24Jul ’24
  3. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed November 7, 2025. Cited figures are marked; the original filing is the authoritative source.

On November 6, 2025, the Compensation Committee of Rivian Automotive, Inc.'s Board of Directors cancelled the performance-based option granted to CEO Dr. Robert J.

Scaringe in January 2021 (covering up to 20,355,946 shares) and granted him a new option to purchase up to 36,500,000 shares of Class A Common Stock under the 2021 Incentive Award Plan. The filing states the new award represents a net increase of 16,144,054 shares underlying the option compared with the 2021 award, and that the Committee does not intend to grant additional discretionary equity awards to Dr. Scaringe during 2026. The exercise price is $15.22a per share, the November 6, 2025 closing price.

Dr. Scaringe's annual base salary was also increased from $1,000,000 to $2,000,000b. The new award is entirely at-risk. Up to 22,000,000 shares can be earned through eleven stock price hurdles from $40 to $140, representing premiums to the exercise price of 163% to 820%, measured by the average closing price over any 120 consecutive trading days within a ten-year term.

Up to 14,500,000 shares can be earned through adjusted operating income and cash flow from operations targets with performance measured through December 31, 2032. The filing states that vesting of the stock-price-based tranches would reflect nearly $153 billionc in incremental stockholder value compared with the Company's current market capitalization. The Committee said the award is designed to retain and incentivize Dr. Scaringe through the next phase of the technology roadmap and the launch of R2.

Separately, Mind Robotics, LLC, a subsidiary of newly formed Mind Robotics, Inc., issued 1,000,000 common units to Dr. Scaringe for his service as Chair of Mind Robotics. The units, approved by a special committee of disinterested and independent directors, are fully vested and give him up to a 10%d economic interest in Mind Robotics once profits and gains exceed a specified threshold after issuance.

Key Highlights

  1. Rivian cancelled CEO Robert J. Scaringe's January 2021 performance option (20,355,946 shares) and replaced it with a new option on up to 36,500,000 Class A shares, a net increase of 16,144,054 shares.
  2. The new option has an exercise price of $15.22 per share, the November 6, 2025 closing price.
  3. Up to 22,000,000 shares are tied to stock price hurdles from $40 to $140 (premiums of 163% to 820% to the exercise price), measured over a ten-year term.
  4. Up to 14,500,000 shares are tied to full-year adjusted operating income and cash flow from operations targets through December 31, 2032.
  5. The filing states vesting of the stock price tranches would reflect nearly $153 billion in incremental stockholder value compared with current market capitalization.
  6. Dr. Scaringe's annual base salary increased from $1,000,000 to $2,000,000, and the Committee does not intend to grant additional discretionary equity awards to him in 2026.
  7. Mind Robotics issued Dr. Scaringe 1,000,000 fully vested profits interest units for his service as Chair, providing up to a 10% economic interest in Mind Robotics above a profit threshold.

Frequently Asked Questions

  1. Why did Rivian replace the CEO's 2021 performance award?

    The filing says the Committee cancelled the 2021 award because the lack of incentive it provided was due to the unlikeliness of attaining its performance goals. The new 2025 CEO Award is intended to retain and incentivize Dr. Scaringe through the next phase of the technology roadmap and the R2 launch, which the Committee believes is in the best interests of the Company and its stockholders.

  2. How much of the new CEO award can actually vest?

    The award is entirely at-risk. Shares vest only if performance goals are met and Dr. Scaringe remains CEO on the scheduled vesting dates. Up to 22,000,000 shares depend on stock price hurdles, and up to 14,500,000 depend on adjusted operating income and cash flow from operations targets. Limited acceleration applies in certain termination or change-in-control events, and forfeiture applies for termination for cause.

  3. What stock prices must be reached for the stock-based tranches to vest?

    Eleven tranches of 2,000,000 shares each are tied to hurdles ranging from $40 to $140 in $10 increments. Hurdles are measured by the average closing price over any 120 consecutive trading days ending no later than the tenth anniversary of the grant date. Any tranche whose hurdle is not met during the ten-year term does not vest.

  4. What is the Mind Robotics profits interest and how does it affect Dr. Scaringe?

    Mind Robotics, LLC issued Dr. Scaringe 1,000,000 common units in connection with his service as Chair of Mind Robotics, Inc. The units were fully vested on issuance and give him up to a 10% economic interest in Mind Robotics once profits and gains exceed a specified threshold. The filing says the common unit agreement will be filed with the Company's next Form 10-K.